PLK1 and diffuse large B-cell lymphoma: Pre-clinical studies suggest that lymphoma cells, particularly those of T-cell origin, may be particularly vulnerable to such agents [45], and the PLK1 inhibitor MLN0905 has shown in vivo activity in DLBCL xenograft models [20].